title: [Agonist of V2 vasopressin receptor reduces depressive disorders in post-stroke patients].
abstract: Poststroke depression is one of the common psychiatric complications after stroke. Thus, the research of new ways for treatment depressed mood after stroke is actual. The previous researches revealed vasopressin to be effective in patients with memory, speech and motor function disorders after stroke. The purpose of the study was to investigate influence of vasopressin on depression after stroke. Fourteen patients with affective disorders have been treated with subendocrine doses of 1-desamino-8-D-arginin-vasopressin (DDAVP) daily by intranasal application during 1,5-2 months. Vasopressin was effective in correcting both apatoadinamic and anxious depression. Treatment effect was durable, lasts for 0,5-1 year after the first course of therapy. The results of this pilot study demonstrate perspective of using selective agonist of vasopressin V2 receptors, DDAVP, in therapy of post-stroke depression.
authors: S G
authors: SG
authors: Belokoskova
authors: I I
authors: II
authors: Stepanov
authors: S G
authors: SG
authors: Tsikunov
mesh_terms: D000281:Administration, Intranasal; D000368:Aged; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D017483:Receptors, Vasopressin / Q000819:agonists*; D012890:Sleep; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy; D020521:Stroke / Q000150:complications*
chemical_list: D017483:Receptors, Vasopressin; D003894:Deamino Arginine Vasopressin